RBC reiterates Outperform on ACADIA Pharmaceuticals stock

Published on 10/06/2026 at 09:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 308.0 million, up 16.00 percent year over year. ACADIA Pharmaceuticals stock costs EUR 18.03 on October 6, 2026 after EUR 17.92.

ACAD, US0042251084, Illustration mit AI erstellt.

ACADIA Pharmaceuticals (ISIN US0042251084) was trading at EUR 18.03 at Lang & Schwarz on October 6, 2026 at 9:34 a.m. CEST, up 0.61 percent versus the prior close of EUR 17.92. The move follows a difficult clinical update, while RBC Capital reiterated an Outperform rating and a USD 37.00 price target on October 5, 2026, as Investing.com reported.

RADIANT result resets the pipeline

ACADIA Pharmaceuticals disclosed Phase 2 topline results for remlifanserin in Alzheimer disease psychosis on September 24, 2026. The 60 milligram dose produced a change from baseline of minus 12.6 on the SAPS-H+D measure versus minus 10.4 for placebo, with a standardized effect size of 0.26 and a p-value of 0.0603, according to StockTitan.

The result missed the primary endpoint, but the same filing said the company would continue enrolling two Phase 3 studies while amending the program and removing the 30 milligram dose arm. That leaves the pipeline dependent on execution in later-stage studies rather than on the initial Phase 2 readout alone.

Revenue growth gives ACAD a counterweight

Acadia reported GAAP total revenue of USD 308.0 million for the second quarter of 2026, up 16.00 percent from USD 265.0 million in the second quarter of 2025. Net income reached USD 32.0 million, or USD 0.18 in diluted earnings per share, while NUPLAZID net sales rose to USD 183.0 million and DAYBUE net sales reached USD 125.0 million, StockTitan reported.

Acadia also raised its 2026 total revenue guidance to USD 1.24 billion to USD 1.30 billion and DAYBUE sales guidance to USD 480.0 million to USD 510.0 million. The combination of higher commercial revenue and a setback for remlifanserin creates a clear split in the investment case: marketed products are producing growth, while the pipeline must rebuild confidence.

Analysts keep a wide valuation spread

RBC Capital maintained its USD 37.00 target on October 5, 2026, according to Investing.com. Other analyst actions were more cautious: Citigroup cut its target from USD 40.00 to USD 33.00, and Needham reduced its target from USD 41.00 to USD 35.00 on September 25, 2026, according to MarketBeat.

MarketBeat listed a consensus target of USD 32.76 and 14 Buy ratings against four Holds on October 3, 2026. The stock's primary listing is Nasdaq, and its USD 19.57 to USD 30.96 52-week range shows that the current US-market quotation remains near the lower end of its annual span.

ACADIA stock stays near its yearly low

ACADIA Pharmaceuticals was trading at EUR 18.03 at Lang & Schwarz on October 6, 2026 at 9:34 a.m. CEST, plus 0.61 percent versus the Lang & Schwarz prior close of EUR 17.92 on October 5, 2026. The company reported USD 307.96 million of revenue and USD 31.50 million of net income for the second quarter of 2026, keeping commercial execution central as investors assess the RADIANT setback.